-
公开(公告)号:US5667775A
公开(公告)日:1997-09-16
申请号:US471747
申请日:1995-06-06
IPC分类号: A61K9/14 , A61K31/00 , A61K31/785 , A61K31/795 , A61K45/08 , A61K47/30 , A61P3/00 , C08F8/00 , C08F20/00 , C08F20/02 , C08F20/52 , C08F22/38 , C08F26/00 , C08F26/02 , C08G59/40 , C08G73/00 , C08G73/02 , C08K5/02 , C08K5/09 , C08K5/11 , C08K5/1515 , C08K5/29 , C08L39/02 , C08L79/02
CPC分类号: A61K31/662 , A61K31/785 , A61K31/795
摘要: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
摘要翻译: 提供磷酸盐结合聚合物用于从胃肠道除去磷酸盐。 口服聚合物,可用于治疗高磷血症。
-
公开(公告)号:US07459151B2
公开(公告)日:2008-12-02
申请号:US11295159
申请日:2005-12-06
IPC分类号: A61K31/74 , A61K31/785
CPC分类号: A61K31/662 , A61K31/785 , A61K31/795
摘要: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
摘要翻译: 提供磷酸盐结合聚合物用于从胃肠道除去磷酸盐。 口服聚合物,可用于治疗高磷血症。
-
公开(公告)号:US06264937B1
公开(公告)日:2001-07-24
申请号:US09166453
申请日:1998-10-05
IPC分类号: A61K31785
CPC分类号: A61K31/765 , A61K31/78 , A61K31/785 , A61K2300/00
摘要: The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inibitors, for example, lipstatin and tetrahydrolipstatin.
摘要翻译: 本发明涉及一种治疗肥胖症的方法,一种减少膳食脂肪吸收的方法,以及用于治疗患者中的高甘油三酯血症的方法以及用于该方法或用于制备药物的具体聚合物。 所述方法包括向哺乳动物(例如人)口服施用治疗有效量的一种或多种脂肪结合聚合物的步骤。 本发明的脂肪结合聚合物的施用有利于在消化之前从身体去除脂肪,具有最小的副作用和低毒性。 在一个优选的实施方案中,一种或多种脂肪结合聚合物与一种或多种脂肪酶不孕症组合施用,例如,脂抑素和四氢孕激素。
-
公开(公告)号:US6083495A
公开(公告)日:2000-07-04
申请号:US929784
申请日:1997-09-15
IPC分类号: A61K9/14 , A61K31/00 , A61K31/785 , A61K31/795 , A61K45/08 , A61K47/30 , A61P3/00 , C08F8/00 , C08F20/00 , C08F20/02 , C08F20/52 , C08F22/38 , C08F26/00 , C08F26/02 , C08G59/40 , C08G73/00 , C08G73/02 , C08K5/02 , C08K5/09 , C08K5/11 , C08K5/1515 , C08K5/29 , C08L39/02 , C08L79/02
CPC分类号: A61K31/662 , A61K31/785 , A61K31/795
摘要: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
-
公开(公告)号:US20090226392A1
公开(公告)日:2009-09-10
申请号:US12256615
申请日:2008-10-23
IPC分类号: A61K31/785 , A61P39/04
CPC分类号: A61K31/662 , A61K31/785 , A61K31/795
摘要: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
摘要翻译: 提供磷酸盐结合聚合物用于从胃肠道除去磷酸盐。 口服聚合物,可用于治疗高磷血症。
-
公开(公告)号:US5925379A
公开(公告)日:1999-07-20
申请号:US826197
申请日:1997-03-27
申请人: W. Harry Mandeville, III , Stephen Randall Holmes-Farley , Thomas X. Neenan , George M. Whitesides
发明人: W. Harry Mandeville, III , Stephen Randall Holmes-Farley , Thomas X. Neenan , George M. Whitesides
IPC分类号: A61K31/74 , A61K31/785 , A61K9/10 , A61K47/32
CPC分类号: A61K31/74 , A61K31/785 , Y10S514/824 , Y10S525/903
摘要: The present invention relates to a method for removing bile salts from a patient, comprising the step of administering to the patient a therapeutically effective amount of a polymer network composition comprising a cationic polymer. In one embodiment, the polymer network is an interpenetrating polymer network. In another embodiment, the polymer network is a semi-interpenetrating polymer network.
摘要翻译: 本发明涉及一种从患者中除去胆汁盐的方法,包括向患者施用治疗有效量的包含阳离子聚合物的聚合物网络组合物的步骤。 在一个实施方案中,聚合物网络是互穿聚合物网络。 在另一个实施方案中,聚合物网络是半互穿聚合物网络。
-
7.
公开(公告)号:US06858203B2
公开(公告)日:2005-02-22
申请号:US10322904
申请日:2002-12-17
IPC分类号: A61K9/14 , A61K31/00 , A61K31/785 , A61K31/795 , A61K45/08 , A61K47/30 , A61P3/00 , C08F8/00 , C08F20/00 , C08F20/02 , C08F20/52 , C08F22/38 , C08F26/00 , C08F26/02 , C08G59/40 , C08G73/00 , C08G73/02 , C08K5/02 , C08K5/09 , C08K5/11 , C08K5/1515 , C08K5/29 , C08L39/02 , C08L79/02
CPC分类号: A61K31/662 , A61K31/785 , A61K31/795
摘要: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
摘要翻译: 提供磷酸盐结合聚合物用于从胃肠道除去磷酸盐。 口服聚合物,可用于治疗高磷血症。
-
8.
公开(公告)号:US06509013B1
公开(公告)日:2003-01-21
申请号:US09542329
申请日:2000-04-04
IPC分类号: A61K31785
CPC分类号: A61K31/662 , A61K31/785 , A61K31/795
摘要: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
摘要翻译: 提供磷酸盐结合聚合物用于从胃肠道除去磷酸盐。 口服聚合物,可用于治疗高磷血症。
-
公开(公告)号:US07041280B2
公开(公告)日:2006-05-09
申请号:US10187316
申请日:2002-06-27
申请人: Stephen Randall Holmes-Farley , W. Harry Mandeville, III , Pradeep K. Dhal , Chad Cori Huval , Xinhua Li , Steven Craig Polomoscanik
发明人: Stephen Randall Holmes-Farley , W. Harry Mandeville, III , Pradeep K. Dhal , Chad Cori Huval , Xinhua Li , Steven Craig Polomoscanik
IPC分类号: A61K31/80
CPC分类号: C08F8/42 , A61K31/74 , A61K31/785 , A61K47/58 , C08F8/44 , C08G65/331 , C08G73/0206 , C08G79/08 , C08F20/60 , C08F26/02
摘要: Disclosed are polymers comprising one or more phenyl boronate ester, boronamide or boronate thioester groups. The phenyl boronate ester, boronamide and boronate thioester groups are represented by one of the following structural formulas: Ar in Structural Formulas (I) and (II) is substituted or unsubstituted; and each Z is —O—, —NH— or —S— and is independently selected. Pharmaceutically acceptable salts of the polymer are also included. The aryl boronate ester, boronamide or boronate thioester can be cleaved to release the corresponding aryl boronic acid.Also disclosed are pharmaceutical compositions comprising the polymers of the present invention and a pharmaceutically acceptable carrier or diluent; and methods of treating a subject for obesity with the polymers of the present invention.
-
公开(公告)号:US06858592B2
公开(公告)日:2005-02-22
申请号:US10187397
申请日:2002-06-27
申请人: Stephen Randall Holmes-Farley , W. Harry Mandeville, III , Pradeep K. Dhal , Chad Cori Huval , Xinhua Li
发明人: Stephen Randall Holmes-Farley , W. Harry Mandeville, III , Pradeep K. Dhal , Chad Cori Huval , Xinhua Li
CPC分类号: C07F5/025 , A61K31/74 , A61K31/785
摘要: Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z′ are independently —O—. —NH— or —S—. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is —H, an amine, —[NH—(CH2)q]r—NH2, halogen, —CF3, thiol ammonium, alcohol, —COOH, —SO3H, —OSO3H or phosphonium group covalently bonded to the terminal position of R. Each —NH— in —[NH—(CH2)q]r—NH2 is optionally N-alkylated or N,N-dialkylated and —NH2 in —[NH—(CH2)q]r—NH2 is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5. R1 and R1′ are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [—N+(R1a)—]. Each R1 is Structural Formula (I) is preferably —H. R1a is —H, alkyl, substituted alkyl, phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.
摘要翻译: 公开了由结构式(I)表示的苯基硼酸化合物:Ar是取代或未取代的芳基.Z和Z'独立地是-O-。 -NH-或-S-X是吸电子基团.R是任选地包含一个或多个胺,铵,醚,硫醚或亚苯基连接基团的取代或未取代的直链烃基,Y是-H,胺, - [NH-(CH 2)q] r -NH 2,卤素,-CF 3,硫醇铵,醇,-COOH,-SO 3 H,-OSO 3 H或共价键合到R的末端的鏻基团。 NH-(CH 2)q] r -NH 2任选被N-烷基化或N,N-二烷基化,-NH 2在 - [NH-(CH 2)q] r -NH 2中任选地N-烷基化,N,N-二烷基化或N ,N,N-三烷基化.q为2至约10的整数,r为1至约5.R1的整数,R1'独立地为-H,脂族基团,取代的脂族基团,芳基或 取代的芳基,或者一起是任选地包含胺连接基团[-N +(R 1a) - ] - 的C 2 -C 5取代或未取代的亚烷基。 每个R1是结构式(I)优选-HR 1a是-H,烷基,取代的烷基,苯基或取代的苯基。还公开了通过给予有效量的由 结构式(I)和包含该化合物和药学上可接受的载体或稀释剂的药物组合物。
-
-
-
-
-
-
-
-
-